以介入治疗为基础的中晚期肝癌综合治疗进展

摘要/Abstract

黄金华, 黄职妹, 张天奇, 韩雪. 以介入治疗为基础的中晚期肝癌综合治疗进展[J]. 肝癌电子杂志, 2019, 6(4): 27-31.

图/表 1

参考文献 50

[1]	Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2018,68(6):394-424.
[2]	Villanueva A . Hepatocellular Carcinoma[J]. The New England journal of medicine, 2019,380(15):1450-62.
[3]	Forner A, Reig M, Bruix J . Hepatocellular carcinoma[J]. Lancet (London, England), 2018,391(10127):1301-14.
[4]	Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis Staging, and Treatment of Patients With Hepatocellular Carcinoma[J]. Gastroenterology, 2016,150(4):835-53.
[5]	Pinter M, Hucke F, Graziadei I , et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib[J]. Radiology, 2012,263(2):590-9.
[6]	Kudo M . Systemic Therapy for Hepatocellular Carcinoma: 2017 Update[J]. Oncology, 2017, 93 Suppl 1: 135-46.
[7]	Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects[J]. Seminars in liver disease, 2010,30(1):61-74.
[8]	Llovet JM, Ricci S, Mazzaferro V , et al. Sorafenib in advanced hepatocellular carcinoma[J]. The New England journal of medicine, 2008,359(4):378-90.
[9]	El-Khoueiry AB, Sangro B, Yau T , et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet (London, England), 2017,389(10088):2492-502.
[10]	Kudo M, Finn RS, Qin S , et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet (London, England), 2018,391(10126):1163-73.
[11]	Zhu AX, Finn RS, Edeline J , et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. The Lancet Oncology, 2018,19(7):940-52.
[12]	Bruix J, Qin S, Merle P , et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet (London, England), 2017,389(10064):56-66.
[13]	亚太影像引导下肿瘤微创治疗协会, 中国抗癌协会肿瘤微创治疗专业委员会, 亚洲肿瘤消融学会(2017)[J]. 肝细胞癌微创与多学科综合诊疗——2018广州共识. 介入放射学杂志, 2019,28:609-23.
[14]	Cerrito L, Annicchiarico BE, Iezzi R , et al. Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers[J]. World journal of gastroenterology, 2019,25(31):4360-82.
[15]	Xue TC, Xie XY, Zhang L , et al. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis[J]. BMC gastroenterology, 2013,13:60.
[16]	Zhu K, Huang J, Lai L , et al. Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation[J]. Radiology, 2018,288(1):300-7.
[17]	Shi F, Wu M, Lian SS , et al. Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes[J]. Radiology, 2019,181991.
[18]	陈奇峰, 贾振宇, 杨正强 , 等. 肝动脉化疗栓塞联合微波消融与单独肝动脉化疗栓塞治疗大肝癌疗效 meta 分析[J]. 介入放射学杂志, 2017,26:225-31.
[19]	Zhang TQ, Huang SM, Gu YK , et al. Sequential and Simultaneous 4-Antenna Microwave Ablation in an Ex Vivo Bovine Liver Model[J]. Cardiovascular and interventional radiology, 2019,42(10):1466-74.
[20]	Zhang TQ, Huang ZM, Shen JX , et al. Safety and effectiveness of multi-antenna microwave ablation-oriented combined therapy for large hepatocellular carcinoma[J]. Therap Adv Gastroenterol, 2019,12:1756284819862966.
[21]	孙永琨 . 2018《CSCO原发性肝癌诊疗指南》解读—全身治疗部分[J]. 肝癌电子杂, 2018,5:11-4.
[22]	中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版). 临床肝胆病杂志, 2017, 8; 33:1419-31.
[23]	Lyu N, Lin Y, Kong Y , et al. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018,67(2):395-6.
[24]	Lyu N, Kong Y, Mu L , et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. Journal of hepatology, 2018,69(1):60-9.
[25]	Yoon SM, Ryoo BY, Lee SJ , et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial[J]. JAMA oncology, 2018,4(5):661-9.
[26]	Shen L, Xi M, Zhao L , et al. Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib[J]. Cancers, 2018,10(12).
[27]	Zhu K, Chen J, Lai L , et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study[J]. Radiology, 2014,272(1):284-93.
[28]	Huang M, Lin Q, Wang H , et al. Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study[J]. European radiology, 2016,26(10):3428-36.
[29]	Zhang L, Hu B, Li W , et al. (125)I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review[J]. Cardiovascular and interventional radiology, 2019.
[30]	Luo JJ, Zhang ZH, Liu QX , et al. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus[J]. Hepatol Int, 2016,10(1):185-95.
[31]	Wang G, Zhang F, Yang B , et al. Feasibility and Clinical Value of CT-guided (125)I Brachytherapy for Bilateral Lung Recurrences from Colorectal Carcinoma[J]. Radiology, 2016,278(3):897-905.
[32]	高飞, 顾仰葵, 黄金华 , 等. CT引导下125Ⅰ近距离治疗肝癌腹膜后转移性淋巴结的临床价值[J]. 中华医学杂志, 2013,93:2155-7.
[33]	Kelley RK, Verslype C, Cohn AL , et al. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study[J]. Annals of oncology : official journal of the European Society for Medical Oncology, 2017,28(3):528-34.
[34]	Kudo M . Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial[J]. Liver cancer, 2018,7(3):225-34.
[35]	Lencioni R, Llovet JM, Han G , et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial[J]. Journal of hepatology, 2016,64(5):1090-8.
[36]	Meyer T, Fox R, Ma YT , et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2017,2(8):565-75.
[37]	He MK, Zou RH, Li QJ , et al. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis[J]. Cardiovascular and interventional radiology, 2018,41(5):734-43.
[38]	He M, Li Q, Zou R , et al. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial[J]. JAMA oncology, 2019.
[39]	Ghodadra A, Bhatt S, Camacho JC , et al. Abscopal Effects and Yttrium-90 Radioembolization[J]. Cardiovascular and interventional radiology, 2016,39(7):1076-80.
[40]	Rao P, Escudier B, de Baere T . Spontaneous regression of multiple pulmonary metastases after radiofrequency ablation of a single metastasis[J]. Cardiovascular and interventional radiology, 2011,34(2):424-30.
[41]	Li F, Guo Z, Lizee G , et al. Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients[J]. Clin Chem Lab Med, 2014,52(9):1357-65.
[42]	Ayaru L, Pereira SP, Alisa A , et al. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization[J]. J Immunol, 2007,178(3):1914-22.
[43]	Huang ZM, Li W, Li S , et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients[J]. Journal of immunotherapy (Hagerstown, Md : 1997), 2013,36(5):287-93.
[44]	Valsecchi ME, Terai M, Eschelman DJ, et al. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases[J]. Journal of vascular and interventional radiology : JVIR, 2015, 26(4): 523-32.e2.
[45]	Nakamoto Y, Mizukoshi E, Kitahara M , et al. Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization[J]. Clinical and experimental immunology, 2011,163(2):165-77.
[46]	Duffy AG, Ulahannan SV, Makorova-Rusher O , et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. Journal of hepatology, 2017,66(3):545-51.
[47]	Khan KA, Kerbel RS . Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa[J]. Nature reviews Clinical oncology, 2018,15(5):310-24.
[48]	Huang Y, Kim BYS, Chan CK , et al. Improving immune-vascular crosstalk for cancer immunotherapy[J]. Nature reviews Immunology, 2018,18(3):195-203.
[49]	Keda M, Sung M W, Kudo M, et al. A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results[J]. Annals of Oncology. 2019, 30(Suppl_5): mdz247. 073.
[50]	Finn Richard, Ducreux Michel, Qin Shukui , et al. ( 2018). IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma[J]. Journal of Clinical Oncology. 36. DOI: 10.1200/JCO.2018.36.15_suppl.TPS4141.

以介入治疗为基础的中晚期肝癌综合治疗进展

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 50

相关文章 0

编辑推荐

Metrics

本文评价